Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.49 |
| ▸ | RELA | Q04206 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24068101 | 0.87 | L3MBTL1 (0.39) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL25730226 | 0.84 | L3MBTL1 (0.37) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL24529400 | 0.84 | NPC1 (0.36) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL15828609 | 0.83 | TNKS (0.43) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL30256773 | 0.81 | GRM5 (0.43) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL22490650 | 0.76 | L3MBTL1 (0.43) | L3MBTL1KMT2ANUDT1 | |
| SCHEMBL15896757 | 0.74 | GRM5 (0.42) | NFKB1LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24529246 | 0.73 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL27181579 | 0.73 | MAOB (0.37) | L3MBTL1 | |
| SCHEMBL25310547 | 0.73 | NUDT1 (0.45) | CYP3A4ALDH1A1L3MBTL1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667257-B | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20230203031-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | ELI LILLY AND COMPANY | 2023-06-29 | — | — | US | disclosed |
| EP-4157840-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | Eli Lilly and Company (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-115667257-A | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-108276352-B | Nitrogen-containing heterocyclic compound with nematicidal activity and preparation method and application thereof | 华东理工大学 | 2022-09-20 | — | — | CN | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203031-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | CDK7, CDK3, CCNH | SMN1; SMN2 2349/4885NPC1 3062/4885RAB9A 1871/4885 |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | SMN1; SMN2 2046/4885NPC1 241/4885RAB9A 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.